Abstract Details

A Phase 1, Open-label, Single Center Study of KYV-101, an Autologous Fully-human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis
Multiple Sclerosis
S3 - Multiple Sclerosis: Clinical Trials (1:00 PM-1:12 PM)
001

We are conducting a Phase 1 prospective clinical trial assessing the feasibility and safety of treating subjects with progressive Multiple Sclerosis with chimeric antigen receptor T cells (CAR-T cells) with a CD-19+ glycoprotein binding site.

To assess the feasibility and safety of treating non-relapsing progressive phenotypes of Multiple Sclerosis with chimeric antigen receptor (CAR-T) immunotherapy with a CD-19+ binding site.

Phase 1 open label prospective study of a fully humanized CAR-T immunotherapy (KYV-101 Hu19-CD828Z) in a dose ranging 3 x 3 design for subjects with Multiple Sclerosis by 2017 McDonald criteria, with progressive worsening disease according to the 2014 Lublin phenotypic criteria. 12 subjects age 18-65 undergo apheresis, lymphodepletion, and infusion of autologously derived lentivirus engineered CAR-T/CD-19 cells at an initial dose of 33 million to 100 million cells IV with inpatient observation over 8 days with assiduous serological and clinical monitoring.

Study recruitment is  active and ongoing. Treated subjects to date have not experienced Cytokine Release Syndrome (CRS), Immune Effector Cell Associated Neurotoxicity (ICANS), or adverse events graded higher than CTCAE Version 5 Grade 1. We observed robust CAR-T cell expansion and CNS penetration. Correlative studies revealed changes in levels of various cytokines, interleukins and other immune markers over the course of post CAR-T treatment, with most pronounced changes indicative of peak immunomodulation detected at Day 14 post-infusion.  

We report initial results of a Phase 1 open-label trial of CAR-T/CD-19 immunotherapy in progressive Multiple Sclerosis. Subjects enrolled to date have shown excellent tolerance without CRS, ICANS or greater than Grade 1 adverse events according to the CTCAE Version 5 rating scale. CAR-T/CD-19 IV infusion generated robust in vivo CAR-T cell proliferation, robust CNS penetration, and evidence of peak immunomodulation at Day 14 post-infusion. This Phase 1 clinical trial is ongoing.
Authors/Disclosures
Jeffrey E. Dunn, MD, FAAN (Stanford University Medical Center)
PRESENTER
Dr. Dunn has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Dunn has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. The institution of Dr. Dunn has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Progentec Diagnostics. Dr. Dunn has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyverna Therapeutics. Dr. Dunn has received intellectual property interests from a discovery or technology relating to health care.
Kristin M. Galetta, MD (Stanford University) Dr. Galetta has received personal compensation in the range of $0-$499 for serving as a Speaker with AAN.
Anna J. Tomczak, MSc (Stanford) Miss Tomczak has nothing to disclose.
Garrett M. Timmons, MD (Stanford Neurology) Dr. Timmons has nothing to disclose.
Crystal Ton-Nu (Stanford University School of Medicine) Crystal Ton-Nu has nothing to disclose.
Julia Sumera (Stanford Neurology) Miss Sumera has nothing to disclose.
Emma A. Martinez Emma A. Martinez has nothing to disclose.
robert lowsky, MD Dr. lowsky has nothing to disclose.